All In Biotech

Drug Trial Radar · NCT05723692

A First-In-Human SAD and MAD Study to Evaluate the Safety, Tolerability, PK and PD of SC Administered ALTB-268 in Healthy Volunteers

A First-In-Human, Randomized, Double-Blind, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered ALTB-268 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Feb 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

56

Actual

Start

Jan 17, 2023

Primary completion

Oct 27, 2023

Study completion Oct 27, 2023

Sponsor

Lead sponsor
AltruBio Inc.Industry
Sponsor type
Industry
Collaborators
ICON plc
First posted
Feb 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study with ALTB-268 will determine the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of ALTB-268 in healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

  • ALTB-268Biological

    monoclonal antibody

  • PlaceboOther

    formulation buffer

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of ALTB-268 Treatment-Emergent Adverse EventsTime frame: through study completion, up to day 120 of the study

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ICON Early Development Services

    Lenexa, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.